142 related articles for article (PubMed ID: 24298632)
1. [Opinion DGVS the IQWiG report for early benefit assessment of aflibercept for the treatment of metastatic colorectal cancer according to § 35a SGB V on May 29, 2013].
Z Gastroenterol; 2013 Aug; 51(8):1019-22. PubMed ID: 24298632
[No Abstract] [Full Text] [Related]
2. Ziv-aflibercept (Zaltrap) for metastatic colorectal cancer.
Med Lett Drugs Ther; 2013 Apr; 55(1415):e36. PubMed ID: 23836346
[No Abstract] [Full Text] [Related]
3. [Boceprevir-benefit assessment by the Institute for Quality and Efficiency in Health Care (IQWiG) in accordance with § 35a SGB V (dosage evaluation)].
Dignass A; Faiss S; Galle P; Layer P; Lerch M; Malfertheiner P; Wehrmann T; Zeuzem S;
Z Gastroenterol; 2012 Jan; 50(1):20-1. PubMed ID: 22222793
[No Abstract] [Full Text] [Related]
4. [Telaprevir-benefit assessment of the Institute for Quality and Efficiency in Health Care (IQWiG) in accordance with § 35a SGB V (dosing evaluation)].
Z Gastroenterol; 2012 Mar; 50(3):271-2. PubMed ID: 22383281
[No Abstract] [Full Text] [Related]
5. Pharmacokinetic and pharmacodynamic evaluation of aflibercept for the treatment of colorectal cancer.
Sanz-Garcia E; Saurí T; Tabernero J; Macarulla T
Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):995-1004. PubMed ID: 25988772
[TBL] [Abstract][Full Text] [Related]
6. [New data confirm it: Zaltrap prolongs survival of all sub-populations with metastatic colorectal cancer ].
Rev Med Suisse; 2014 May; 10(431):1114-5. PubMed ID: 24941681
[No Abstract] [Full Text] [Related]
7. Phase II clinical and pharmacokinetic study of aflibercept in patients with previously treated metastatic colorectal cancer.
Tang PA; Cohen SJ; Kollmannsberger C; Bjarnason G; Virik K; MacKenzie MJ; Lourenco L; Wang L; Chen A; Moore MJ
Clin Cancer Res; 2012 Nov; 18(21):6023-31. PubMed ID: 22977191
[TBL] [Abstract][Full Text] [Related]
8. Targeted therapy for metastatic colorectal cancer: role of aflibercept.
Mitchell EP
Clin Colorectal Cancer; 2013 Jun; 12(2):73-85. PubMed ID: 23102896
[TBL] [Abstract][Full Text] [Related]
9. Ziv-aflibercept (Zaltrap) for the treatment of metastatic colorectal cancer.
Perkins SL; Cole SW
Ann Pharmacother; 2014 Jan; 48(1):93-8. PubMed ID: 24259608
[TBL] [Abstract][Full Text] [Related]
10. Is there a benefit from addiction to anti-VEGF therapy in patients with colorectal cancer?
Saif MW
Anticancer Res; 2013 Jun; 33(6):2377-80. PubMed ID: 23749885
[TBL] [Abstract][Full Text] [Related]
11. The value and effectiveness of angiogenesis inhibitors for colorectal cancer.
Venook AP
Clin Adv Hematol Oncol; 2015 Sep; 13(9):561-3. PubMed ID: 26452184
[No Abstract] [Full Text] [Related]
12. [New molecular-targeted agents for colorectal cancer - regorafenib and aflibercept].
Kato S
Gan To Kagaku Ryoho; 2013 Jan; 40(1):6-9. PubMed ID: 23306912
[TBL] [Abstract][Full Text] [Related]
13. Understanding the mechanisms of action of antiangiogenic agents in metastatic colorectal cancer: a clinician's perspective.
Clarke JM; Hurwitz HI; Rangwala F
Cancer Treat Rev; 2014 Oct; 40(9):1065-72. PubMed ID: 25047778
[TBL] [Abstract][Full Text] [Related]
14. [Joint opinion of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) and the German Society for Internal Medicine (DGIM) to Vedolizumab-benefit assessment according to § 35a SGB V the G-BA].
Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten
Z Gastroenterol; 2015 Jan; 53(1):54-8. PubMed ID: 25932477
[No Abstract] [Full Text] [Related]
15. Emerging VEGF-receptor inhibitors for colorectal cancer.
Martinelli E; Troiani T; Morgillo F; Orditura M; De Vita F; Belli G; Ciardiello F
Expert Opin Emerg Drugs; 2013 Mar; 18(1):25-37. PubMed ID: 23216053
[TBL] [Abstract][Full Text] [Related]
16. Ziv-aflibercept: binding to more than VEGF-A--does more matter?
Clarke JM; Hurwitz HI
Nat Rev Clin Oncol; 2013 Jan; 10(1):10-1. PubMed ID: 23149898
[TBL] [Abstract][Full Text] [Related]
17. [Statement of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) for teduglutide-benefit assessment according to § 35a SGB V the G-BA].
Schreiber S
Z Gastroenterol; 2015 Feb; 53(2):143-4. PubMed ID: 25821868
[No Abstract] [Full Text] [Related]
18. Aflibercept in lung cancer.
Neal JW; Wakelee HA
Expert Opin Biol Ther; 2013 Jan; 13(1):115-20. PubMed ID: 23199019
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of aflibercept in the treatment of metastatic colorectal cancer.
Macarulla T; Sauri T; Tabernero J
Expert Opin Biol Ther; 2014 Oct; 14(10):1493-505. PubMed ID: 25152076
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetic analysis of free and bound aflibercept in patients with advanced solid tumors.
Thai HT; Veyrat-Follet C; Mentré F; Comets E
Cancer Chemother Pharmacol; 2013 Jul; 72(1):167-80. PubMed ID: 23673444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
